Back


28/08/2019
First patient included in menstrual migraine study
Asarina Pharma AB (publ) (ASAP: FN Stockholm) today announced the first patient has been included in its Phase IIa trial of Sepranolone in menstrual migraine (MM). The study will include 80-90 patients and is expected to be completed by the end of 2020. [...]

Download the pdf file





X

X